US Stocks
US Options
Emerging Asia
GBP Cash Savings
Charts & Tools
Paper Trading
Extended Hours
Wall Street Journal
TradingViewK
KNSA
Kiniksa Pharmaceuticals Internat…
42.44
0.61+1.46%Closed16:58 01/22 EST
OPEN/PREV CLOSE41.83/41.83
TODAY RANGE41.22-42.75
VOL903.98K
MARKET CAP3.22B
52 WEEK RANGE18.12-44.42
AVG VOL (3M)509.55K
% TURNOVER1.19%
TURNOVER0
P/E (TTM)94.67
% RANGE3.66%
EPS(TTM)0.4483
P/E(FORWARD)47.69
P/B5.98
BVPS7.10
DIVIDEND--
P/S7.27
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.85B
SHARES OUTSTANDING75.80M
NEXT EARNINGS02/16-02/27
FREE FLOAT43.66M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·01/15 02:33
Kiniksa Pharmaceuticals International (KNSA) Is Down 6.7% After Raising 2026 ARCALYST Revenue Outlook - Has The Bull Case Changed?
TipRanks·01/14 22:00
Kiniksa Pharmaceuticals Reshapes Leadership With New COO, CSO
Dow Jones·01/13 14:01
Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush
Dow Jones·01/13 14:01
Kiniksa Pharmaceuticals Price Target Raised to $50.00/Share From $48.00 by Wedbush
TipRanks·01/13 13:46
Kiniksa price target raised to $50 from $48 at Wedbush
Simply Wall St·01/13 12:20
A Look At Kiniksa Pharmaceuticals (KNSA) Valuation After ARCALYST Update And Pipeline Progress
Seeking Alpha·01/12 13:28
Kiniksa Pharmaceuticals sees ARCALYST net product revenue between $900M-$920M for 2026
Reuters·01/12 12:43
BRIEF-Kiniksa Pharmaceuticals Provides Corporate Update
TipRanks·01/12 12:43
Kiniksa provides corporate update
Reuters·01/12 12:30
Kiniksa Projects Continued Annual Cash Flow Positivity for 2026
Same Industry
Name/Symbol
Change%
Price